Liu Qingsong [Photo provided to chinadaily.com.cn]

Liu Qingsong is a researcher at the Hefei Institute of Material Science of the Chinese Academy of Sciences, chairman of Hefei Precedo Pharmaceuticals Co Ltd and one of the leading scientific and technological talents.

In 2006, he graduated from Texas A&M University in the United States and was then engaged in post-doctoral research into anti-cancer drugs at Harvard Medical School. After joining the Chinese Academy of Sciences in 2012, he independently constructed a BaF3 engineering cell bank containing more than 220 cells and developed more than 20 clinical candidate targeted drugs. He is currently carrying out clinical trials on a national class I targeted drug. He has contributed to a technology system for clinical precision drug research, based on high-throughput in vitro drug sensitivity experiments.

Liu has published more than 110 articles in international journals, with a total impact factor of 820 and has received a total of more than 7,600 citations. He has 52 patent applications and 12 of them have been authorized. His 11 molecular probe products for scientific research have entered into market and more than 10 of his patents have been transferred to companies.

Liu has won the 10th Anhui Province Youth Science and Technology Innovation Excellence Award, the Chinese Academy of Sciences Young Scientist Award, the Chinese Pharmaceutical Association Yiling Biomedical Youth Award and the Anhui Province Innovation Competition Award. Liu's team won the 22nd China Youth Group Medal.

Liu serves as a member of the Standing Committee of the Anhui Science and Technology Association, a member of the Standing Committee of the Anhui Pharmaceutical Association and head of the precision medicine treatment committee.